ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.69 CNY | 0.00% |
|
+6.30% | +6.95% |
| Apr. 24 | Huahai Pharmaceutical Gets Approval to Market Busulfan Injection | MT |
| Apr. 19 | Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
15.69
CNY
Average target price
16.37
CNY
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.95% | 3.19B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharma Wins Nod to Market Generic High Blood Pressure Tablets in US
